- Home
- MYD vs TRVI Comparison
MYD vs TRVI Comparison
Compare MYD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYD
- TRVI
- Stock Information
- Founded
- MYD 1991
- TRVI 2011
- Country
- MYD United States
- TRVI United States
- Employees
- MYD N/A
- TRVI N/A
- Industry
- MYD Investment Bankers/Brokers/Service
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MYD Finance
- TRVI Health Care
- Exchange
- MYD Nasdaq
- TRVI Nasdaq
- Market Cap
- MYD 460.1M
- TRVI 383.4M
- IPO Year
- MYD N/A
- TRVI 2019
- Fundamental
- Price
- MYD $10.33
- TRVI $6.61
- Analyst Decision
- MYD
- TRVI Strong Buy
- Analyst Count
- MYD 0
- TRVI 8
- Target Price
- MYD N/A
- TRVI $17.56
- AVG Volume (30 Days)
- MYD 253.1K
- TRVI 1.3M
- Earning Date
- MYD 01-01-0001
- TRVI 05-08-2025
- Dividend Yield
- MYD 4.55%
- TRVI N/A
- EPS Growth
- MYD N/A
- TRVI N/A
- EPS
- MYD N/A
- TRVI N/A
- Revenue
- MYD N/A
- TRVI N/A
- Revenue This Year
- MYD N/A
- TRVI N/A
- Revenue Next Year
- MYD N/A
- TRVI N/A
- P/E Ratio
- MYD N/A
- TRVI N/A
- Revenue Growth
- MYD N/A
- TRVI N/A
- 52 Week Low
- MYD $8.76
- TRVI $2.30
- 52 Week High
- MYD $11.30
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- MYD 55.52
- TRVI 56.38
- Support Level
- MYD $10.21
- TRVI $6.37
- Resistance Level
- MYD $10.36
- TRVI $7.24
- Average True Range (ATR)
- MYD 0.13
- TRVI 0.42
- MACD
- MYD 0.05
- TRVI -0.01
- Stochastic Oscillator
- MYD 95.52
- TRVI 50.38
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.